CELL LINES

Contributor Information
- Name Anne Lykkesfeldt
- Institute Danish Cancer Society
- Primary citation Kirkegaard et al. 2014. Cancer Lett. 344(1):90-100. PMID: 24513268.
Tool Details
- Tool name: T47D-182R-1 Cell Line
- Tool type: Cell Lines
- Tool sub-type: Continuous
- Parental cell line: T47D
- Organism: Human
- Tissue: Breast
- Cancer type: Breast cancer
- Disease: Cancer
- Model: Tumour line
- Application: Determining molecular mechanisms around fulvestrant resistance
-
Description: The T47D-182R-1 cell line is an adherent breast cancer cell line resistant to fulvestrant (Faslodex). It is derived from the human breast cancer cell line - T47D/S5 by long term treatment with 100 nM fulvestrant. T47D-182R-1 is adherent and the morphology is epithelial.
Resistance will inevitably occur for the second-line therapy fulvestrant. Therefore, this is a highly valuable tool in extending knowledge of acquired therapeutic resistance to ultimately find targeted treatments to resistant tumour cells. As well as treament that can inhibit or delay the emergence of resistance. - Research area: Cancer; Drug development
- Production details: Human breast cancer cell line derived from T47D/S5 by long term treatment with 100 nM fulvestrant. Grow with 5% fetal bovine serum and 100 nM fulvestrant. Oestrogen and progesterone receptor negative.Passage 166 (AL3372, AL3381)
- Cellosaurus ID: CVCL_1D34
- For Research Use Only
Target Details
- Target: Oestrogen receptor
Application Details
- Application: Determining molecular mechanisms around fulvestrant resistance
- Application notes: Oestrogen and progesterone receptor negative.
Handling
- Format: Frozen
- Passage number: Passage 166 (AL3372, AL3381)
- Growth medium: Phenol red free RPMI 1640 + 5% FCS + glutamax + 8ug Insulin/ml + 100 nM fulvestrant. Grow with 5% fetal bovine serum and 100 nM fulvestrant.
- Temperature: 37° C
- Atmosphere: 5% CO2
- Shipping conditions: Dry ice
Related Tools
References
- • Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.
- • Larsen et al. 2015. BMC Cancer. 15(1):1-15. PMID: 25885472.
- • Kirkegaard et al. 2014. Cancer Lett. 344(1):90-100. PMID: 24513268.